Equillium, Inc.

Equillium, Inc. is a biotechnology company focused on developing novel therapeutics for severe autoimmune and inflammatory disorders. Its pipeline includes EQ504, an aryl hydrocarbon receptor modulator being developed for the treatment of ulcerative colitis and other gastrointestinal conditions, with potential expansion into inflammatory lung diseases. The company is also evaluating EQ302, an orally administered bi-specific inhibitor of IL-15 and IL-21 designed to address gastrointestinal disorders such as celiac disease. Equillium focuses on addressing unmet medical needs across gastroenterology, dermatology, and pulmonology.

The company conducts its operations in the United States, utilizing dedicated office and laboratory spaces to support its research and drug development activities. Its research efforts and strategic corporate operations are based in California, with presence in San Diego and La Jolla. Equillium's principal executive offices and corporate headquarters are located in La Jolla, California.

Summary of the business section of Equillium's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we employed 14 employees, of which 13 were full-time employees, who were engaged in research and development activities, operations, finance, business development or administration.”